Morgan Stanley’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Morgan Stanley’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-68,557	Closed	-$20.4K	–	7828
2023 Q2	$20.4K	Sell	68,557 -9,738	-12%	-$2.94K	﹤0.01%	6562
2023 Q1	$33.9K	Buy	78,295 +16,228	+26%	+$12.5K	﹤0.01%	6424
2022 Q4	$73.2K	Buy	62,067 +13,027	+27%	+$21.2K	﹤0.01%	6118
2022 Q3	$113K	Buy	49,040 +32,118	+190%	+$84.1K	﹤0.01%	6016
2022 Q2	$38K	Buy	16,922 +11,222	+197%	+$77.8K	﹤0.01%	6738
2022 Q1	$55K	Buy	5,700 +5,200	+1,040%	+$46.6K	﹤0.01%	6665
2021 Q4	$5K	Sell	500 -153	-23%	-$1.52K	﹤0.01%	7664
2021 Q3	$7K	Buy	+653	New	+$6.4K	﹤0.01%	7432

Morgan Stanley's GRNA Position: Q3 2023 in Review

Morgan Stanley sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 68,557 shares — an estimated $20.4K sold.

Morgan Stanley first reported a position in GRNA in Q3 2021 and held it in 8 quarters. The position peaked at $113K in Q3 2022. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

Morgan Stanley reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
Morgan Stanley sold 68,557 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $20.4K.
Morgan Stanley first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q3 2021 and held it in 8 quarters.
Morgan Stanley's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $113K in Q3 2022.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.